Amylyx Pharmaceuticals (AMLX) EBIT Margin Growth (3y) (2024)
Powered by 
Analysis
Amylyx Pharmaceuticals (AMLX) EBIT Margin Growth (3y) (2024) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 210.98 Bn | 196.99 Bn | 7.24 Bn | -347.00 |
| 2 | Gilead Sciences | 181.24 Bn | 178.06 Bn | 6.22 Bn | -15,844.00 |
| 3 | Vertex Pharmaceuticals | 132.38 Bn | 124.53 Bn | 2.84 Bn | -377.00 |
| 4 | Regeneron Pharmaceuticals | 82.97 Bn | 74.97 Bn | 3.93 Bn | -204.00 |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn | 7,045.00 |
| 6 | Moderna | 54.80 Bn | 49.67 Bn | 52.00 Mn | -1,934.00 |
| 7 | Alnylam Pharmaceuticals | 34.09 Bn | 30.78 Bn | 992.69 Mn | 9,003.00 |
| 8 | Biogen | 31.34 Bn | 30.05 Bn | 1.96 Bn | -2,825.00 |
| 9 | Roivant Sciences | 30.11 Bn | 30.11 Bn | 1.16 Mn | -2.41 Mn |
| 10 | Amylyx Pharmaceuticals | 3.68 Bn | 3.68 Bn | - | - |